Indian Diabetes & Endocrine Supplier & Wholesale Distributor.

Diabetes is the fastest-growing non-communicable disease of the decade. The IDF Diabetes Atlas puts global prevalence at 537 million adults in 2021, rising to an estimated 783 million by 2045, with the sharpest rates of increase across the Middle East, North Africa, sub-Saharan Africa and Southeast Asia — our primary export lanes. Insulin access, metformin continuity and oral-antidiabetic breadth are the three things a ministry programme depends on, and all three are manufacturing-and-logistics problems before they are clinical ones.

Our insulin lines (human insulin regular and NPH, glargine, lispro, aspart, detemir, degludec, premix 30/70 and 70/30 presentations) ship under 2–8°C validated cold-chain with continuous logger data handed over at destination. The WHO Prequalification programme has added biosimilar insulins to its list; we source from prequalified and GMP-audited origin where the tender specifies it. Oral antidiabetics — metformin, glimepiride, gliclazide, vildagliptin, sitagliptin, empagliflozin, dapagliflozin — ship at ambient.

Thyroid (levothyroxine, carbimazole, methimazole), adrenal (hydrocortisone, prednisolone, dexamethasone) and bone-metabolism lines (alendronate, risedronate, zoledronic acid, calcitriol) round out the endocrine shelf. 471 lines across 60 molecules. One supplier, one dossier trail, one cold-chain process, for the whole endocrine programme.